Francis Medical – a privately-held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer- announced the completion of the company’s oversubscribed $80 million Series C equity funding, the most significant fundraising round to date for the company. Arboretum Ventures and Solas BioVentures co-led the Series C round. And new investors Orlando Health Ventures and two additional strategic partners joined this round, along with previous investors Coloplast A/S and Tonkawa.
This funding will advance the VAPOR 2 pivotal clinical study for managing prostate cancer and the development and U.S. commercialization of its Vanquish Water Vapor Ablation proprietary prostate cancer treatment, expected by the end of 2025.
The VAPOR 2 study is a prospective, multicenter, and single-arm study that evaluates the safety and efficacy of the Vanquish Water Vapor Ablation System for prostate cancer. And data gathered from the VAPOR 2 study will support 510(k) clearance, which the company expects to file for in July 2025.
Previously, the company was awarded FDA Breakthrough Device status for Vanquish on the strength of its VAPOR 1 Early Feasibility Study, published in the Journal of Endocrinology in November 2022. And the VAPOR 1 study reported no serious adverse events, no device-related adverse events, and no unanticipated adverse device effects as its primary endpoint. In 87% of patients treated, six-month biopsy results indicated no remaining Gleason Grade Group 2 or greater clinically significant disease in the targeted treatment areas.
As the second most common cancer in U.S. men, the American Cancer Society estimates that 1 in 8 American men will be diagnosed with prostate cancer during their lifetime. And prostate cancer is a severe disease often treated with therapies that cause complications, such as urinary incontinence and erectile dysfunction. Francis Medical’s Vanquish device’s thermal water vapor energy technology is a breakthrough therapy designed for using phase shift energy stored in sterile water vapor to convectively transfer thermal energy to cancerous tissue, causing cell death. Through this process, damage to surrounding structures can be minimized or eliminated by respecting the prostate’s natural boundaries. Vanquish aims to be a revolutionary cancer therapy that is tough on cancer yet gentle on patients.
KEY QUOTES:
“We’re extremely proud to be joining this funding round and investing in Francis Medical’s development of a groundbreaking, disruptive therapeutic solution to treat prostate cancer. Vanquish is an innovative therapy that has the potential to revolutionize the way prostate cancer is treated, by safely and effectively ablating the cancerous tissue while minimizing or eliminating thermal damage to the nerves and surrounding prostate tissue, thus reducing adverse events associated with radical prostatectomy and radiation therapies.”
– David Strong, president and CEO of Orlando Health
“This milestone is an important step forward in the fight to vanquish prostate cancer. We are excited to be bringing this therapy to the U.S. market in late 2025 and are incredibly grateful to our investor partners for their dedication to making a meaningful difference in the lives of prostate cancer patients and are more confident than ever that this groundbreaking technology will ultimately become the first-line treatment of choice for men and their doctors.”
– Michael Kujak, president and CEO of Francis Medical
